Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- erdafitinib
- mavorixafor
Interactions between your drugs
erdafitinib mavorixafor
Applies to: erdafitinib, mavorixafor
Erdafitinib may alter the blood levels and effects of mavorixafor. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
mavorixafor food
Applies to: mavorixafor
Mavorixafor should be taken on an empty stomach after an overnight fast, 30 minutes before food. Do not consume grapefruit products during treatment with mavorixafor unless otherwise directed by your doctor. Grapefruit juice can increase the blood levels and adverse effects of mavorixafor, increasing the risk of experiencing a change in the electrical activity of your heart called QT prolongation, which can result in irregular heartbeats that can be life-threatening. You should seek immediate medical attention if you experience an irregular heartbeat or feel dizzy, lightheaded, or faint during treatment. Speak with your doctor or healthcare provider if you have any questions. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Padcev
Padcev (enfortumab vedotin) is an antibody-drug conjugate that is given as an intravenous infusion ...
Bavencio
Bavencio (avelumab) is a cancer medicine that interferes with the growth and spread of cancer cells ...
Balversa
Balversa (erdafitinib) is an oral kinase inhibitor that may be used to treat adults with locally ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Avelumab
Avelumab is used for merkel cell carcinoma, renal cell carcinoma, urothelial carcinoma
Enfortumab vedotin
Enfortumab vedotin is used for bladder cancer, urothelial carcinoma
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.